Listing 1 - 4 of 4 |
Sort by
|
Choose an application
Fluorodeoxyglucose F18 --- Fluorine Radioisotopes --- Soft Tissue Neoplasms --- Dideoxynucleosides --- Tomography, Emission-Computed --- Sarcoma --- Sarcoma, Epithelioid --- Sarcoma, Soft Tissue --- Sarcoma, Spindle Cell --- Epithelioid Sarcoma --- Epithelioid Sarcomas --- Sarcomas --- Sarcomas, Epithelioid --- Sarcomas, Soft Tissue --- Sarcomas, Spindle Cell --- Soft Tissue Sarcoma --- Soft Tissue Sarcomas --- Spindle Cell Sarcoma --- Spindle Cell Sarcomas --- ddNus --- 2',3'-Dideoxynucleosides --- Dideoxyribonucleosides --- 2',3' Dideoxynucleosides --- Neoplasm, Soft Tissue --- Neoplasms, Soft Tissue --- Soft Tissue Neoplasm --- Neoplasms, Connective Tissue --- Radioisotopes, Fluorine --- Fluorine --- 18F-FDG --- Fluorine-18-fluorodeoxyglucose --- Fluorodeoxyglucose F 18 --- 18F Fluorodeoxyglucose --- 18FDG --- 2-Fluoro-2-deoxy-D-glucose --- 2-Fluoro-2-deoxyglucose --- Fludeoxyglucose F 18 --- 2 Fluoro 2 deoxy D glucose --- 2 Fluoro 2 deoxyglucose --- F 18, Fludeoxyglucose --- F 18, Fluorodeoxyglucose --- F18, Fluorodeoxyglucose --- Fluorine 18 fluorodeoxyglucose --- Fluorodeoxyglucose, 18F --- diagnostic use --- radionuclide imaging --- methods --- Theses --- diagnostic use.
Choose an application
The aim of this book is to provide crisp information related to pathology, management and radiological/molecular imaging in breast carcinoma, along with detailed information on FDG PET-CT in breast cancer, normal variants, artefacts, pitfalls with atlas illustrations. The book is unique in providing quick reference to practice of PET/CT in breast cancer. The initial few chapters are related to the pathology and management of breast carcinoma to help understand the pathophysiology of breast cancer before going to the imaging. The chapter on imaging in breast cancer highlights the role of different imaging modalities for different indications to the reader. The last four chapters describe in detail the role, normal variants, artefacts and pitfalls of FDG PET/CT along with recent molecular imaging advances in breast cancer. Written by Pathology, Oncology, Radiology and Nuclear Medicine experts from different countries with enormous experience in breast cancer practice, the book addresses nuclear medicine physicians and radiologists, but it may be of interest to a wider medical community, including oncologists and radiotherapists. .
Breast Neoplasms --- Fluorodeoxyglucose F18 --- Positron Emission Tomography Computed Tomography. --- Molecular Imaging. --- diagnostic imaging. --- Imaging, Molecular --- CT PET --- CT PET Scan --- PET CT Scan --- PET-CT --- PET-CT Scan --- Positron Emission Tomography-Computed Tomography --- CT PET Scans --- CT Scan, PET --- CT Scans, PET --- PET CT Scans --- PET Scan, CT --- PET Scans, CT --- PET-CT Scans --- Scan, CT PET --- Scan, PET CT --- Scan, PET-CT --- Scans, CT PET --- Scans, PET CT --- Scans, PET-CT --- 18F-FDG --- Fluorine-18-fluorodeoxyglucose --- Fluorodeoxyglucose F 18 --- 18F Fluorodeoxyglucose --- 18FDG --- 2-Fluoro-2-deoxy-D-glucose --- 2-Fluoro-2-deoxyglucose --- Fludeoxyglucose F 18 --- 2 Fluoro 2 deoxy D glucose --- 2 Fluoro 2 deoxyglucose --- F 18, Fludeoxyglucose --- F 18, Fluorodeoxyglucose --- F18, Fluorodeoxyglucose --- Fluorine 18 fluorodeoxyglucose --- Fluorodeoxyglucose, 18F --- Nuclear medicine. --- Radiology. --- Oncology. --- Nuclear Medicine. --- Atomic medicine --- Radioisotopes in medicine --- Medical radiology --- Radioactive tracers --- Radioactivity --- Tumors --- Radiological physics --- Physics --- Radiation --- Physiological effect
Choose an application
Positron emission tomography (PET) is a very useful technique for medical diagnosis and drug development. Radiopharmaceuticals are a key element in PET techniques and one of the pivotal factors influencing the applications of PET. The aim of this Special Issue of Molecules is to report on the recent research work on a number of aspects of PET radiopharmaceuticals and their preclinical and clinical use. More specifically, the content of this Special Issue includes but is not limited to radiolabeling design, radiosynthesis, synthesis techniques, quality control methodologies, GMP production methods, product formulation, in vitro and in vivo preclinical PET evaluations, clinical evaluations, dosimetry, stability study and metabolite analysis, and modeling.
Medicine --- kinetic analysis --- Siglec-9 --- gallium-68 --- vascular adhesion protein --- VAP-1 --- infection --- inflammation --- osteomyelitis --- animal model --- Staphylococcus aureus --- multiple myeloma --- positron emission tomography/computed tomography --- radiopharmaceuticals --- 18F-fluorodeoxyglucose --- tetrazine ligation --- PET --- SPECT --- indium-11 --- fluorine-18 --- positron emission tomography (PET), defluorination --- isotopic exchange --- silicon-based fluoride acceptor --- bioorthogonal chemistry --- tetrazine --- inverse electron-demand Diels-Alder ligation --- opioid --- naloxone --- overdose --- fentanyl --- carfentanil --- [11C]carfentanil --- positron emission tomography --- receptor occupancy --- pharmacokinetics --- [18F]AlF --- NOTA --- NODAGA --- PODS --- thiol-reactive --- linker --- affibody molecule --- bioconjugation --- EGFR --- tumor imaging --- vulnerable plaque --- molecular imaging --- PET imaging --- nanobody --- single-domain antibody --- sub-millimetre resolution --- AlF-radiolabelling --- preclinical radiopharmaceutical dosimetry --- image-based internal dosimetry --- OLINDA --- MCT1/MCT4 lactate transporter inhibitor --- [18F]FACH --- radiation safety --- sigma-1 receptor availability --- orthotopic xenograft of glioblastoma in mouse --- small animal Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) --- (S)-(−)-[18F]fluspidine --- imaging-based biomarker --- SV2A protein --- PET radiotracers --- synaptic loss --- radiochemistry --- preclinical development --- clinical outcomes --- monocarboxylate transporters (MCTs) --- FACH --- 18F-labeled analog of FACH --- α-CCA --- blood-brain barrier (BBB) --- positron emission tomography (PET) imaging --- peptides --- proteolysis --- metabolic stability --- kinetic analysis --- Siglec-9 --- gallium-68 --- vascular adhesion protein --- VAP-1 --- infection --- inflammation --- osteomyelitis --- animal model --- Staphylococcus aureus --- multiple myeloma --- positron emission tomography/computed tomography --- radiopharmaceuticals --- 18F-fluorodeoxyglucose --- tetrazine ligation --- PET --- SPECT --- indium-11 --- fluorine-18 --- positron emission tomography (PET), defluorination --- isotopic exchange --- silicon-based fluoride acceptor --- bioorthogonal chemistry --- tetrazine --- inverse electron-demand Diels-Alder ligation --- opioid --- naloxone --- overdose --- fentanyl --- carfentanil --- [11C]carfentanil --- positron emission tomography --- receptor occupancy --- pharmacokinetics --- [18F]AlF --- NOTA --- NODAGA --- PODS --- thiol-reactive --- linker --- affibody molecule --- bioconjugation --- EGFR --- tumor imaging --- vulnerable plaque --- molecular imaging --- PET imaging --- nanobody --- single-domain antibody --- sub-millimetre resolution --- AlF-radiolabelling --- preclinical radiopharmaceutical dosimetry --- image-based internal dosimetry --- OLINDA --- MCT1/MCT4 lactate transporter inhibitor --- [18F]FACH --- radiation safety --- sigma-1 receptor availability --- orthotopic xenograft of glioblastoma in mouse --- small animal Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) --- (S)-(−)-[18F]fluspidine --- imaging-based biomarker --- SV2A protein --- PET radiotracers --- synaptic loss --- radiochemistry --- preclinical development --- clinical outcomes --- monocarboxylate transporters (MCTs) --- FACH --- 18F-labeled analog of FACH --- α-CCA --- blood-brain barrier (BBB) --- positron emission tomography (PET) imaging --- peptides --- proteolysis --- metabolic stability
Choose an application
Positron emission tomography (PET) is a very useful technique for medical diagnosis and drug development. Radiopharmaceuticals are a key element in PET techniques and one of the pivotal factors influencing the applications of PET. The aim of this Special Issue of Molecules is to report on the recent research work on a number of aspects of PET radiopharmaceuticals and their preclinical and clinical use. More specifically, the content of this Special Issue includes but is not limited to radiolabeling design, radiosynthesis, synthesis techniques, quality control methodologies, GMP production methods, product formulation, in vitro and in vivo preclinical PET evaluations, clinical evaluations, dosimetry, stability study and metabolite analysis, and modeling.
kinetic analysis --- Siglec-9 --- gallium-68 --- vascular adhesion protein --- VAP-1 --- infection --- inflammation --- osteomyelitis --- animal model --- Staphylococcus aureus --- multiple myeloma --- positron emission tomography/computed tomography --- radiopharmaceuticals --- 18F-fluorodeoxyglucose --- tetrazine ligation --- PET --- SPECT --- indium-11 --- fluorine-18 --- positron emission tomography (PET), defluorination --- isotopic exchange --- silicon-based fluoride acceptor --- bioorthogonal chemistry --- tetrazine --- inverse electron-demand Diels-Alder ligation --- opioid --- naloxone --- overdose --- fentanyl --- carfentanil --- [11C]carfentanil --- positron emission tomography --- receptor occupancy --- pharmacokinetics --- [18F]AlF --- NOTA --- NODAGA --- PODS --- thiol-reactive --- linker --- affibody molecule --- bioconjugation --- EGFR --- tumor imaging --- vulnerable plaque --- molecular imaging --- PET imaging --- nanobody --- single-domain antibody --- sub-millimetre resolution --- AlF-radiolabelling --- preclinical radiopharmaceutical dosimetry --- image-based internal dosimetry --- OLINDA --- MCT1/MCT4 lactate transporter inhibitor --- [18F]FACH --- radiation safety --- sigma-1 receptor availability --- orthotopic xenograft of glioblastoma in mouse --- small animal Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) --- (S)-(−)-[18F]fluspidine --- imaging-based biomarker --- SV2A protein --- PET radiotracers --- synaptic loss --- radiochemistry --- preclinical development --- clinical outcomes --- monocarboxylate transporters (MCTs) --- FACH --- 18F-labeled analog of FACH --- α-CCA --- blood-brain barrier (BBB) --- positron emission tomography (PET) imaging --- peptides --- proteolysis --- metabolic stability
Listing 1 - 4 of 4 |
Sort by
|